Novel Therapy Receives FDA RMAT Designation in Localized Prostate Cancer
Full results from the phase 3 trial supporting CAN-2409 plus valacyclovir and radiation therapy in this indication will be presented at the 2025 ASCO Annual Meeting.
FOLFIRINOX Improves PFS in Locally Advanced Pancreatic Cancer
Phase 3 data may support FOLFIRINOX as a standard of care in fit patients with locally advanced pancreatic cancer.
Eftilagimod Alfa/Pembrolizumab/RT Elicit Pathologic Responses in Sarcoma
Eftilagimod alfa with pembrolizumab and radiotherapy exceeded the median tumor hyalinization/fibrosis vs historical benchmarks in resectable soft tissue sarcomas.
QOL/Continence Differences Remain Stable for TNT/CRT Groups in Rectal Cancer
A 6-year analysis of the phase 3 STELLAR trial did not find any significant differences between total neoadjuvant treatment and concurrent chemoradiation in rectal cancer.
TPS 43 ADELA: A Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus vs Elacestrant + Placebo in ER+/HER2– Advanced Breast Cancer Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy
ASCO 2025: Key Anticipated Updates Across Cancer Care
Experts highlight research at the 2025 ASCO Annual Meeting that may move the needle in gynecologic cancers, hematologic malignancies, and other fields.
High-Dose CCRT Plus Durvalumab May Be Safe, Efficacious in Stage III NSCLC
Patients who received 70 Gy of radiotherapy had a significantly longer duration of treatment than those who received less than 70 Gy.
EBC-129 Receives FDA Fast-Track Designation for PDAC
Clinical data from a phase 1 trial evaluating EBC-129 in solid tumors will be presented at the 2025 American Society of Clinical Society Annual Meeting.
Revolutionizing Onco-Dermatology Techniques and Managing Adverse Effects
Scalp-cooling may enhance patients’ quality of life when managing hair loss associated with cancer treatment.
PROs Support Safety of Durvalumab Plus Platinum/Etoposide in ES-SCLC
Select adverse effects examined during the initial 24 weeks of treatment occurred at a rare or occasional frequency and mild-to-moderate severity.
Managing Dermatologic Complications in Oncology
Diverse dermatologic AEs, such as hair and nail toxicities, can be associated with various cancer treatments.
45 A Phase 3 Randomized Study of Adjuvant Sacituzumab Tirumotecan Plus Pembrolizumab vs Treatment of Physician’s Choice in Patients With Triple-Negative Breast Cancer Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response at Surgery
Life-Saving Surgery in Lung Cancer May Be Uncovered Through Information-Seeking
Stage IV lung cancer may be curable based on the success of the DREAM Program, according to thoracic surgeon, Ankit Bharat, MBBS,
Sacituzumab Govitecan Improves PFS in 1L PD-1/PD-L1 Inhibitor Ineligible mTNBC
In the phase 3 ASCENT-03 trial, sacituzumab govitecan did not show an OS detriment vs chemotherapy in previously untreated metastatic triple-negative breast cancer.
Avutometinib/Defactinib Combo May Elicit Efficacy in Metastatic PDAC
Ten of 12 patients with metastatic pancreatic ductal adenocarcinoma given the recommended phase 2 dose of the combination regimen had a response.
IMRT Does Not Improve Tolerability vs 3D-CRT in Advanced Rectal Cancer
Intensity-modulated radiotherapy increased some lower-grade toxicities vs 3D conformal radiotherapy in patients with locally advanced rectal cancer.
Simple vs Radical Hysterectomy Shows Comparable Survival in Cervical Cancer
Less radical surgery did not come at the expense of postoperative metrics, including 30-day readmissions, surgical findings, or receipt of adjuvant therapy.
46 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for High-Risk, Early-Stage Triple-Negative Breast Cancer: Overall Survival and Subgroup Results From the Phase 3 KEYNOTE-522 Study
Integrating Oncodermatology Into Multidisciplinary Practice
Oncodermatology is critical in managing adverse effects from cancer treatments, specifically targeted therapies and immunotherapies.
Elucidating the Safety Profile of Double Lung Transplantation
Ankit Bharat, MBBS, a thoracic surgeon, discussed potential treatment-emergent adverse effects or complications as well as strategies for managing them.
Spotlighting Key Upcoming Presentations Across Oncology at ASCO 2025
Experts in gynecologic cancer, genitourinary malignancies, and other disciplines highlight noteworthy clinical data slated for presentation at ASCO 2025.
48 Prevalence of “HER2 Ultra-Low” Among Advanced Breast Cancer Patients With Historical IHC0 Status
Neoadjuvant SCRT Combo May Prolong Survival in Advanced Rectal Cancer
Among patients with rectal cancer who underwent total mesorectal excision following SCRT plus camrelizumab and chemotherapy, the 3-year OS rate was 93.3%.
Camrelizumab/Apatinib Plus Chemotherapy May Show Promise in ES-SCLC
The safety profile of camrelizumab plus apatinib and chemotherapy in a phase 1 study aligns with prior reports of each agent.
Advancing Research, Novel Technologies to Deliver Exceptional Cancer Care
The Jack & Sheryl Morris Cancer Center offers “state-of-the-art” surgical suites and advanced radiation technology, says Andrew M. Evens, DO, MBA, MSc.
49 Clinical Characteristics and Treatment Persistence in US Patients With HR+/HER2–, Node-Positive Early Breast Cancer Treated With Abemaciclib: Real-World Study From First Year After Approval
Navigating the Landscape of PSMA PET Imaging Agents in Prostate Cancer
Prostate-specific membrane antigen PET imaging has completely altered the landscape of prostate cancer detection and management. Read as several experts discuss the trajectory and growth of these agents.
Chemoimmunotherapy Boosts Pathological Complete Responses in MIBC
Real-world data may support chemotherapy plus immune checkpoint blockade as a promising frontline neoadjuvant therapy for muscle-invasive bladder cancer.
Identifying the Treatment Landscape for Advanced Lung Cancers
Thoracic surgeon Ankit Bharat, MBBS, discussed surgical strategies among patients with advanced lung cancer diagnoses based on staging.
CHMP Recommends Approval of Belantamab Mafodotin Combos in Multiple Myeloma
The European Commission is expected to approve the belantamab mafodotin combinations for this multiple myeloma population in the third quarter of 2025.